Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers
Authors
Keywords
Lynch syndrome, Gynecologic cancers, Immunotherapy, Checkpoint inhibitors, Endometrial cancer, Ovarian cancer, PD-1, PD-L1
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 20, Issue 10, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-23
DOI
10.1007/s11864-019-0676-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
- (2019) Kathleen N Moore et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers
- (2019) Margaret Moore et al. MODERN PATHOLOGY
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma
- (2019) Heidi Britton et al. GYNECOLOGIC ONCOLOGY
- Endometrial Tumor Immune Response: Predictive Biomarker of Response to Immunotherapy
- (2019) Mary M. Mullen et al. CLINICAL CANCER RESEARCH
- Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
- (2019) Larissa Lee et al. GYNECOLOGIC ONCOLOGY
- Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer
- (2019) Casper Reijnen et al. GYNECOLOGIC ONCOLOGY
- Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).
- (2019) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.
- (2019) Nicoletta Colombo et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.
- (2019) Maria M Rubinstein et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
- (2019) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).
- (2019) Yoland Catherine Antill et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.
- (2019) John B. Liao et al. JOURNAL OF CLINICAL ONCOLOGY
- Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer.
- (2019) Katherine Cynthia Fuh et al. JOURNAL OF CLINICAL ONCOLOGY
- Passenger fusion genes are correlated to antitumor effect of anti-PD-1 antibody nivolumab for ovarian cancer
- (2019) J. Hamanishi et al. GYNECOLOGIC ONCOLOGY
- PD-1/PD-L1 expression in mutated ovarian cancers
- (2019) C.A. Penn et al. GYNECOLOGIC ONCOLOGY
- Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
- (2019) E. Pujade-Lauraine et al. GYNECOLOGIC ONCOLOGY
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Immunosuppressive Tumor Microenvironment Status and Histological Grading of Endometrial Carcinoma
- (2019) Julie Antomarchi et al. Cancer Microenvironment
- Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
- (2018) Kathleen A. Cronin et al. CANCER
- Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement
- (2018) Stefania Bellone et al. CLINICAL CANCER RESEARCH
- Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer
- (2018) N.L. Jones et al. GYNECOLOGIC ONCOLOGY
- Mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies: Implications for immune therapy
- (2018) I. Winer et al. GYNECOLOGIC ONCOLOGY
- Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial
- (2018) B.G. Wortman et al. GYNECOLOGIC ONCOLOGY
- Undifferentiated Endometrial Carcinoma, an Immunohistochemical Study Including PD-L1 Testing of a Series of Cases From a Single Cancer Center
- (2018) Maysa Al-Hussaini et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
- (2018) Klaus Pietzner et al. Journal of Gynecologic Oncology
- Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
- (2018) Andrea Varga et al. GYNECOLOGIC ONCOLOGY
- T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers
- (2018) Shiho Asaka et al. MODERN PATHOLOGY
- Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
- (2018) Ying L. Liu et al. Current Oncology Reports
- Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium
- (2017) Brian C Willis et al. MODERN PATHOLOGY
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer
- (2017) Hitomi Yamashita et al. Oncotarget
- Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
- (2017) Florine A. Eggink et al. OncoImmunology
- Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers
- (2017) Christina Son et al. Cancer Management and Research
- Regression of Chemotherapy-Resistant Polymerase (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab
- (2016) A. D. Santin et al. CLINICAL CANCER RESEARCH
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Targeting the programmed cell death-1 pathway in breast and ovarian cancer
- (2016) Leisha A. Emens et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
- (2016) Junzo Hamanishi et al. International Journal of Clinical Oncology
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy
- (2015) T.J. Herzog et al. GYNECOLOGIC ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations
- (2009) E Barrow et al. CLINICAL GENETICS
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
- (2009) Michael A. Bookman et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started